Deoxycholic acid

DB03619

small molecule approved

Deskripsi

Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical procedures.

Struktur Molekul 2D

Berat 392.572
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Deoxycholic acid is rapidly absorbed after subcutaneous administration. After maximum recommended single treatment dose, 100mg, the post-treatment plasma levels returned to endogenous levels within 24 hours. With the proposed treatment guideline, no accumulation is expected.

Metabolisme

Deoxycholic acid is not metabolized to any significant extent under normal conditions.

Rute Eliminasi

The exogenous deoxycholic acid joins the endogenous bile acid pool in the enterohepatic circulation and is excreted unchanged in feces along with endogenous deoxycholic acid.

Interaksi Obat

240 Data
Lepirudin The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Deoxycholic acid.
Bivalirudin The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Deoxycholic acid.
Alteplase The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Deoxycholic acid.
Urokinase The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Deoxycholic acid.
Reteplase The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Deoxycholic acid.
Anistreplase The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Deoxycholic acid.
Tenecteplase The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Deoxycholic acid.
Drotrecogin alfa The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Deoxycholic acid.
Streptokinase The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Deoxycholic acid.
Dicoumarol The risk or severity of bleeding and bruising can be increased when Dicoumarol is combined with Deoxycholic acid.
Argatroban The risk or severity of bleeding and bruising can be increased when Argatroban is combined with Deoxycholic acid.
Ardeparin The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Deoxycholic acid.
Phenindione The risk or severity of bleeding and bruising can be increased when Phenindione is combined with Deoxycholic acid.
Fondaparinux The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Deoxycholic acid.
Warfarin The risk or severity of bleeding and bruising can be increased when Warfarin is combined with Deoxycholic acid.
Pentosan polysulfate The risk or severity of bleeding and bruising can be increased when Pentosan polysulfate is combined with Deoxycholic acid.
Phenprocoumon The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Deoxycholic acid.
Heparin The risk or severity of bleeding and bruising can be increased when Heparin is combined with Deoxycholic acid.
Enoxaparin The risk or severity of bleeding and bruising can be increased when Enoxaparin is combined with Deoxycholic acid.
Acenocoumarol The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Deoxycholic acid.
4-hydroxycoumarin The risk or severity of bleeding and bruising can be increased when 4-hydroxycoumarin is combined with Deoxycholic acid.
Coumarin The risk or severity of bleeding and bruising can be increased when Coumarin is combined with Deoxycholic acid.
Ximelagatran The risk or severity of bleeding and bruising can be increased when Ximelagatran is combined with Deoxycholic acid.
Desmoteplase The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Deoxycholic acid.
Ancrod The risk or severity of bleeding and bruising can be increased when Ancrod is combined with Deoxycholic acid.
Rivaroxaban The risk or severity of bleeding and bruising can be increased when Rivaroxaban is combined with Deoxycholic acid.
Sulodexide The risk or severity of bleeding and bruising can be increased when Sulodexide is combined with Deoxycholic acid.
Semuloparin The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Deoxycholic acid.
Idraparinux The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Deoxycholic acid.
Astaxanthin The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Deoxycholic acid.
Apixaban The risk or severity of bleeding and bruising can be increased when Apixaban is combined with Deoxycholic acid.
Otamixaban The risk or severity of bleeding and bruising can be increased when Otamixaban is combined with Deoxycholic acid.
Amediplase The risk or severity of bleeding and bruising can be increased when Amediplase is combined with Deoxycholic acid.
Dabigatran etexilate The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Deoxycholic acid.
Danaparoid The risk or severity of bleeding and bruising can be increased when Danaparoid is combined with Deoxycholic acid.
Dalteparin The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Deoxycholic acid.
Tinzaparin The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Deoxycholic acid.
(R)-warfarin The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Deoxycholic acid.
Ethyl biscoumacetate The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Deoxycholic acid.
Nadroparin The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Deoxycholic acid.
Ditazole The risk or severity of bleeding and bruising can be increased when Ditazole is combined with Deoxycholic acid.
Edoxaban The risk or severity of bleeding and bruising can be increased when Edoxaban is combined with Deoxycholic acid.
Sodium citrate The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Deoxycholic acid.
Dextran The risk or severity of bleeding and bruising can be increased when Dextran is combined with Deoxycholic acid.
Bemiparin The risk or severity of bleeding and bruising can be increased when Bemiparin is combined with Deoxycholic acid.
Parnaparin The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Deoxycholic acid.
Desirudin The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Deoxycholic acid.
Antithrombin Alfa The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Deoxycholic acid.
Protein C The risk or severity of bleeding and bruising can be increased when Protein C is combined with Deoxycholic acid.
Antithrombin III human The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Deoxycholic acid.
Letaxaban The risk or severity of bleeding and bruising can be increased when Letaxaban is combined with Deoxycholic acid.
Darexaban The risk or severity of bleeding and bruising can be increased when Darexaban is combined with Deoxycholic acid.
Betrixaban The risk or severity of bleeding and bruising can be increased when Betrixaban is combined with Deoxycholic acid.
Nafamostat The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Deoxycholic acid.
Monteplase The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Deoxycholic acid.
Gabexate The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Deoxycholic acid.
Fluindione The risk or severity of bleeding and bruising can be increased when Fluindione is combined with Deoxycholic acid.
Protein S human The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Deoxycholic acid.
Brinase The risk or severity of bleeding and bruising can be increased when Brinase is combined with Deoxycholic acid.
Clorindione The risk or severity of bleeding and bruising can be increased when Clorindione is combined with Deoxycholic acid.
Diphenadione The risk or severity of bleeding and bruising can be increased when Diphenadione is combined with Deoxycholic acid.
Tioclomarol The risk or severity of bleeding and bruising can be increased when Tioclomarol is combined with Deoxycholic acid.
Melagatran The risk or severity of bleeding and bruising can be increased when Melagatran is combined with Deoxycholic acid.
Saruplase The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Deoxycholic acid.
(S)-Warfarin The risk or severity of bleeding and bruising can be increased when (S)-Warfarin is combined with Deoxycholic acid.
Tocopherylquinone The risk or severity of bleeding and bruising can be increased when Tocopherylquinone is combined with Deoxycholic acid.
Dabigatran The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Deoxycholic acid.
Troxerutin The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Deoxycholic acid.
Edetic acid The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Deoxycholic acid.
Reviparin The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Deoxycholic acid.
Dermatan sulfate The risk or severity of bleeding and bruising can be increased when Dermatan sulfate is combined with Deoxycholic acid.
SR-123781A The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Deoxycholic acid.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Deoxycholic acid.
Eptifibatide The risk or severity of adverse effects can be increased when Eptifibatide is combined with Deoxycholic acid.
Ticlopidine The risk or severity of adverse effects can be increased when Ticlopidine is combined with Deoxycholic acid.
Anagrelide The risk or severity of adverse effects can be increased when Anagrelide is combined with Deoxycholic acid.
Clopidogrel The risk or severity of adverse effects can be increased when Clopidogrel is combined with Deoxycholic acid.
Tirofiban The risk or severity of adverse effects can be increased when Tirofiban is combined with Deoxycholic acid.
Pentoxifylline The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Deoxycholic acid.
Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Deoxycholic acid.
Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Deoxycholic acid.
Sulfinpyrazone The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Deoxycholic acid.
Cilostazol The risk or severity of adverse effects can be increased when Cilostazol is combined with Deoxycholic acid.
Ridogrel The risk or severity of adverse effects can be increased when Ridogrel is combined with Deoxycholic acid.
Epoprostenol The risk or severity of adverse effects can be increased when Epoprostenol is combined with Deoxycholic acid.
Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Deoxycholic acid.
Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Deoxycholic acid.
Tesmilifene The risk or severity of adverse effects can be increased when Tesmilifene is combined with Deoxycholic acid.
Defibrotide The risk or severity of adverse effects can be increased when Defibrotide is combined with Deoxycholic acid.
Beraprost The risk or severity of adverse effects can be increased when Beraprost is combined with Deoxycholic acid.
Ibudilast The risk or severity of adverse effects can be increased when Ibudilast is combined with Deoxycholic acid.
Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Deoxycholic acid.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Deoxycholic acid.
Prasugrel The risk or severity of adverse effects can be increased when Prasugrel is combined with Deoxycholic acid.
Cangrelor The risk or severity of adverse effects can be increased when Cangrelor is combined with Deoxycholic acid.
Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Deoxycholic acid.
Triflusal The risk or severity of adverse effects can be increased when Triflusal is combined with Deoxycholic acid.
Ticagrelor The risk or severity of adverse effects can be increased when Ticagrelor is combined with Deoxycholic acid.
Icosapent ethyl The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Deoxycholic acid.
Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Deoxycholic acid.

Target Protein

Proliferating cell nuclear antigen PCNA
Steroid Delta-isomerase ksi
Cytochrome C ppcA
Elongation factor-like GTPase 1 EFL1
Choloylglycine hydrolase cbh
Lactaldehyde dehydrogenase aldA
Multidrug efflux pump subunit AcrB acrB
Cytochrome c oxidase subunit 1 ctaD
Cytochrome c oxidase subunit 2 ctaC
Bile acid receptor NR1H4
Glutathione S-transferase P GSTP1
G-protein coupled bile acid receptor 1 GPBAR1
Glutathione S-transferases (Cytosolic) GSTA1

Referensi & Sumber

Synthesis reference: Filiberto Zadini, Giorgio Zadini, "Deoxycholic acid liposome-based dermatological topical preparation." U.S. Patent US20060222695, issued October 05, 2006.
Artikel (PubMed)
  • PMID: 25724831
    Wollina U, Goldman A: ATX-101 for reduction of submental fat. Expert Opin Pharmacother. 2015 Apr;16(5):755-62. doi: 10.1517/14656566.2015.1019465. Epub 2015 Feb 27.
  • PMID: 25684122
    Walker P, Lee D: A phase 1 pharmacokinetic study of ATX-101: serum lipids and adipokines following synthetic deoxycholic acid injections. J Cosmet Dermatol. 2015 Mar;14(1):33-9. doi: 10.1111/jocd.12122. Epub 2015 Feb 14.

Contoh Produk & Brand

Produk: 7 • International brands: 0
Produk
  • Belkyra
    Solution • 10 mg / mL • Subcutaneous • Canada • Approved
  • Debiline
    Tablet • - • Oral • Canada • Approved
  • Debiline H
    Tablet • - • Oral • Canada • Approved
  • Duchol Ect
    Tablet, delayed release • - • Oral • Canada • OTC • Approved
  • Kybella
    Injection, solution • 20 mg/2mL • Subcutaneous • US • Approved
  • Medichol
    Tablet • - • Oral • Canada • Approved
  • Regubil
    Tablet • - • Oral • Canada • OTC • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul